Purcell Michael J. purchased $100K of CTRVP
Purcell Michael J. purchased 2,000,000 shares of Hepion Pharmaceuticals, Inc. (CTRVP) at $0.05 ($0.10M total) on 2026-08-03.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market purchase size and price, which may modestly influence sentiment but does not change the company’s disclosed fundamentals in this text.
Market read
Traders may treat the transaction as a small bullish signal, but it lacks accompanying fundamental news.
What to watch
The filing notes no 10b5-1 plan and provides a very low per-share price, but the article does not explain motivation, timing constraints, or whether the director already held a large position.
Background
This is an SEC Form 4 insider transaction disclosure for Hepion Pharmaceuticals, Inc.
Ticker impact
Hepion Pharmaceuticals disclosed a director open-market purchase of 2,000,000 shares at $0.0500 on 2026-08-03 via Form 4.
Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.
Form 4 insider purchases can support bullish sentiment, but the article provides no new operational or financial information beyond the transaction details.
Market effects
Minimal; single-company insider transaction without sector-wide signal.
None indicated.
None indicated.
Counterpoint
Insider buying can be routine, tax-related, or part of pre-existing compensation patterns, so it may not reflect a change in fundamentals.
Key entities
- issuerHepion Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure (CTRVP).
- insiderPurcell Michael J.
Director who purchased 2,000,000 shares at $0.0500/share on 2026-08-03.